Don’t forget – sign up for our free daily newsletter to stay in the activist investing know.
Valeant Pharma (VRX) is the easy answer.
Bill Ackman’s Pershing Square Holdings (PSH) is now down 19% year-to-date after being down 7.3% in October. Valeant is a big contributor to that, with the stock off 40% for the last month and down 50% since Ackman went active.
With the fall, it’s moved from his second largest long-only U.S. holding to fifth.
The other major detractor has been his SPAC, Platform Specialty Products (PAH), down 17% over the last month.
He still owns 5.7% of VRX and 20% of PAH. PAH is off 55% since Ackman went active in 2014.
